Sucampo Pharma (SCMP) Tops Q3 EPS by 2c, Guidance Beats

Sucampo Pharma (NASDAQ: SCMP) reported Q3 EPS of $0.28, $0.02 better than the analyst estimate of $0.26. Revenue for the quarter came in at $57.9 million versus the consensus estimate of $51.46 million.

GUIDANCE:

Sucampo Pharma sees FY2016 EPS of $1.20-$1.25, versus the consensus of $1.04. Sucampo Pharma sees FY2016 revenue of $220-225 million, versus the consensus of $205.7 million.

For earnings history and earnings-related data on Sucampo Pharma (SCMP) click here.

You May Also Be Interested In

• Adidas (ADDYY) gains after outlook boost
• WRAP Technologies (WRAP) Provides Update on Operations and Timing of Q4 Report
• Scilex (SCLX) Provides Preliminary Financial Results For Gross and Net Sales for ZTlido® for the First Quarter 2024